Accordingly, current preclinical efforts are focused on optimizing the PSMA-targeting moiety [20,25], linker composition [12,26], and albumin-binding motif [20,26] to maximize the tumor-to-kidney radiation dose ratios. The gene discussed is ALB; the disease is neoplasm.